Each peptide below targets a distinct pathway in the skin-regeneration process. They are presented in order of evidence depth for skin-specific outcomes.
1. GHK-Cu - The Collagen & Gene-Modulation Leader
What it is: GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Plasma levels decline sharply with age, from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60.
Why it leads for skin: GHK-Cu has the deepest evidence base of any peptide for skin-specific outcomes. Broad Institute Connectivity Map analysis shows it modulates more than 4,000 human genes, including genes involved in collagen synthesis, antioxidant defense, anti-inflammatory signaling, and tissue remodeling.
Key human evidence
- 71-woman facial cream trial: 12 weeks of GHK-Cu improved skin laxity, clarity, fine lines, wrinkle depth, and increased skin density and thickness.
- Collagen biopsy study: measurable collagen increases in 70 percent of treated women, compared with 50 percent for vitamin C cream and 40 percent for retinoic acid.
- Wrinkle volume trial: nano-lipid GHK-Cu reduced wrinkle volume by 55.8 percent versus control and 31.6 percent versus Matrixyl 3000 over 8 weeks.
- Eye cream trial: improved skin density, thickness, and lines better than placebo and vitamin K cream.
- 2023 IRB-approved study: 21 women using a GHK-Cu gel showed a 28 percent average increase in collagen density after 3 months.
Mechanism summary: GHK-Cu stimulates collagen I, III, and IV synthesis via dermal fibroblasts; provides the copper cofactor required for lysyl oxidase; activates decorin and glycosaminoglycan production; suppresses inflammatory cytokines via NF-kB inhibition; and activates antioxidant genes that protect against UV-induced oxidative damage.
Dosing reference: GHK-Cu protocol page
Evidence tier: 4 out of 5 - multiple human clinical studies, extensive preclinical data, limited human injectable data.
2. BPC-157 - The Wound-Repair Accelerator
What it is: BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a gastric protein. It is the most widely used peptide in the research community and a common starting compound for peptide users.
Why it matters for skin: BPC-157 accelerates the early phases of wound repair, vascular supply, growth factor signaling, and inflammatory resolution, creating the biological foundation on which later collagen remodeling can build.
- Angiogenesis support through VEGFR2 activation, delivering oxygen and nutrients to damaged skin.
- Burn-healing models where topical BPC-157 outperformed silver sulfadiazine for wound closure and tissue quality.
- Deep wound, diabetic ulcer, and surgical-incision models showing faster repair.
- Increased collagen deposition and granulation tissue formation versus controls.
- Upregulation of EGF, FGF, and VEGF, the core growth factors driving skin repair cascades.
Mechanism summary: BPC-157 activates the FAK-paxillin pathway for cell migration, upregulates VEGFR2 for angiogenesis, modulates the nitric oxide system for vascular support, and interacts with the growth hormone receptor system.
Dosing reference: BPC-157 protocol page
Evidence tier: 3 out of 5 - extensive preclinical data, limited human clinical data, no published human skin-aging trials.
3. TB-500 - The Cell-Migration Engine
What it is: TB-500 is a synthetic 43-amino acid peptide based on the active region of Thymosin Beta-4, a protein found in virtually all mammalian cells and highly concentrated in platelets and wound fluid.
Why it matters for skin: TB-500's primary mechanism, actin regulation, enables the cell migration required to close wound gaps. For skin specifically, it drives keratinocyte and fibroblast migration to injury or aging sites.
- Keratinocyte migration increased 2 to 3 times over controls in wound models.
- Re-epithelialization increased by up to 61 percent at 7 days post-wounding in rat models.
- Increased collagen deposition and new blood vessel formation in treated wounds.
- Accelerated full-thickness wound closure in multiple animal models through cell migration and matrix deposition.
Mechanism summary: TB-500 sequesters G-actin monomers, promoting actin polymerization and enabling cell motility. In skin, that means fibroblasts and keratinocytes can migrate to damaged or collagen-depleted areas faster. It also upregulates laminin-5 production and promotes angiogenesis at wound sites.
Dosing reference: TB-500 protocol page
Evidence tier: 3 out of 5 - strong preclinical wound-healing data, limited human data, no published human skin-aging trials.
4. KPV - The Anti-Inflammatory Environment Controller
What it is: KPV (Lysine-Proline-Valine) is a tripeptide fragment derived from the C-terminal end of alpha-melanocyte-stimulating hormone. Despite being only 3 amino acids long, it retains potent anti-inflammatory activity without the pigmentary effects of the parent hormone.
Why it matters for skin: Chronic low-grade inflammation is a primary driver of skin aging. UV exposure, oxidative stress, and environmental damage create persistent NF-kB activation that degrades collagen faster than it can be replaced. KPV targets that inflammatory environment directly.
- NF-kB inhibition affecting TNF-alpha, IL-6, and IL-1 beta signaling.
- Wound-healing hydrogels that reduced inflammation, promoted tissue regeneration, and showed antimicrobial activity against MRSA.
- Preclinical efficacy comparable to corticosteroids for psoriasis, eczema, and dermatitis models, but without the same immune suppression and tissue thinning concerns.
- Support for collagen synthesis and fibroblast activity while reducing inflammatory collagen degradation.
Mechanism summary: KPV binds melanocortin receptors on immune cells and keratinocytes, suppressing NF-kB-mediated cascades. It reduces TNF-alpha, IL-6, and IL-1 beta while stimulating tissue-repair pathways. Unique among anti-inflammatory agents, it modulates immune activity rather than broadly suppressing it.
Dosing reference: KPV protocol page
Evidence tier: 2 out of 5 - strong mechanistic and preclinical anti-inflammatory data with limited human clinical data.
